TOKAI (9729) Q3 2025 earnings summary

Executive summary

• Net sales for the nine months ended December 31, 2024, rose 8.1% year-over-year to ¥111,765 million, marking a record high for the fourth consecutive year.

• Operating profit decreased 3.3% year-over-year to ¥5,672 million, the first decline in two years, due to higher depreciation, acquisition-related expenses, and increased Pharmacy Services costs.

• Profit attributable to owners of parent increased 6.8% year-over-year to ¥4,409 million.

• Comprehensive income declined 20.4% year-over-year to ¥3,708 million, mainly due to a ¥746 million loss in valuation differences on securities.

Financial highlights

• Gross profit increased to ¥25,931 million from ¥24,957 million year-over-year.

• Ordinary profit was ¥6,188 million, up 0.7% year-over-year.

• Basic earnings per share for the nine months was ¥129.28, up from ¥117.25 in the prior year.

• Net assets decreased to ¥85,477 million from ¥86,789 million at the previous fiscal year-end.

• Total assets as of December 31, 2024, were ¥115,949 million, up from ¥114,926 million at March 31, 2024.

Segment performance

• Healthcare Services net sales grew 7.3% year-over-year; operating profit up 5.6%.

• Pharmacy Services net sales increased 11.4% year-over-year, but operating profit fell 17.3%.

• Environmental Services net sales were flat (+0.2%), with a 5.2% decline in operating profit.